| Mark A Simon, MD | |
|
5401 S Congress Ave, #102, Atlantis, FL 33462-6635 | |
| (561) 967-5033 | |
| (561) 967-8974 |
| Full Name | Mark A Simon |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 43 Years |
| Location | 5401 S Congress Ave, Atlantis, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083654081 | NPI | - | NPPES |
| 05047300 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | ME55192 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jfk Medical Center | Atlantis, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medical Specialists Of The Palm Beaches Inc | 0244143758 | 110 |
News Archive
Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).
We all know people who are able to roll with life's punches, while for others, every misfortune is a jab straight to the gut. Research examining this issue has found that although most people require significant adversity to become depressed - the death of a loved one, say, or getting fired - roughly 30 percent of people with first-time depression and 60 percent of people with a history of depression develop the disorder following relatively minor misfortunes.
Employing technology that reads the entire DNA code, researchers led by the Translational Genomics Research Institute (TGen) and the Technical University of Denmark (DTU) have pinpointed the source of a cholera outbreak in Haiti that killed more than 6,000 people and sickened 300,000.
The New York Times: "Representative Henry A. Waxman is on a crusade to save Medicare billions of dollars — in a way that he says would end up helping the elderly."
Molecular Detection Inc., a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced the first close of a new financing. The financing was led by MentorTech Ventures II, LP and included Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group Fund I and II, LP, all existing investors. The company raised $1.4 million as part of a follow-on to its $3.3 million Series C round announced in late 2009.
› Verified 2 days ago
| Entity Name | Medical Specialists Of The Palm Beaches Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386687580 PECOS PAC ID: 0244143758 Enrollment ID: O20031111000205 |
News Archive
Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).
We all know people who are able to roll with life's punches, while for others, every misfortune is a jab straight to the gut. Research examining this issue has found that although most people require significant adversity to become depressed - the death of a loved one, say, or getting fired - roughly 30 percent of people with first-time depression and 60 percent of people with a history of depression develop the disorder following relatively minor misfortunes.
Employing technology that reads the entire DNA code, researchers led by the Translational Genomics Research Institute (TGen) and the Technical University of Denmark (DTU) have pinpointed the source of a cholera outbreak in Haiti that killed more than 6,000 people and sickened 300,000.
The New York Times: "Representative Henry A. Waxman is on a crusade to save Medicare billions of dollars — in a way that he says would end up helping the elderly."
Molecular Detection Inc., a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced the first close of a new financing. The financing was led by MentorTech Ventures II, LP and included Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group Fund I and II, LP, all existing investors. The company raised $1.4 million as part of a follow-on to its $3.3 million Series C round announced in late 2009.
› Verified 2 days ago
| Entity Name | Ecg Consultants Of Bethesda Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588811533 PECOS PAC ID: 8628134665 Enrollment ID: O20090227000151 |
News Archive
Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).
We all know people who are able to roll with life's punches, while for others, every misfortune is a jab straight to the gut. Research examining this issue has found that although most people require significant adversity to become depressed - the death of a loved one, say, or getting fired - roughly 30 percent of people with first-time depression and 60 percent of people with a history of depression develop the disorder following relatively minor misfortunes.
Employing technology that reads the entire DNA code, researchers led by the Translational Genomics Research Institute (TGen) and the Technical University of Denmark (DTU) have pinpointed the source of a cholera outbreak in Haiti that killed more than 6,000 people and sickened 300,000.
The New York Times: "Representative Henry A. Waxman is on a crusade to save Medicare billions of dollars — in a way that he says would end up helping the elderly."
Molecular Detection Inc., a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced the first close of a new financing. The financing was led by MentorTech Ventures II, LP and included Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group Fund I and II, LP, all existing investors. The company raised $1.4 million as part of a follow-on to its $3.3 million Series C round announced in late 2009.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark A Simon, MD 5700 Lake Worth Rd, #204, Greenacres, FL 33463-4727 Ph: (561) 968-7968 | Mark A Simon, MD 5401 S Congress Ave, #102, Atlantis, FL 33462-6635 Ph: (561) 967-5033 |
News Archive
Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).
We all know people who are able to roll with life's punches, while for others, every misfortune is a jab straight to the gut. Research examining this issue has found that although most people require significant adversity to become depressed - the death of a loved one, say, or getting fired - roughly 30 percent of people with first-time depression and 60 percent of people with a history of depression develop the disorder following relatively minor misfortunes.
Employing technology that reads the entire DNA code, researchers led by the Translational Genomics Research Institute (TGen) and the Technical University of Denmark (DTU) have pinpointed the source of a cholera outbreak in Haiti that killed more than 6,000 people and sickened 300,000.
The New York Times: "Representative Henry A. Waxman is on a crusade to save Medicare billions of dollars — in a way that he says would end up helping the elderly."
Molecular Detection Inc., a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced the first close of a new financing. The financing was led by MentorTech Ventures II, LP and included Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group Fund I and II, LP, all existing investors. The company raised $1.4 million as part of a follow-on to its $3.3 million Series C round announced in late 2009.
› Verified 2 days ago
James Heron, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, #218, Atlantis, FL 33462 Phone: 561-968-0307 Fax: 561-968-7673 | |
Roberto Von Sohsten, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, #102, Atlantis, FL 33462 Phone: 561-967-5033 Fax: 561-967-8974 | |
Dr. Samantha Sylvonne Kerry-ann Nicholson-spence, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-1273 | |
Alexander Chernobelsky, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, #102, Atlantis, FL 33462 Phone: 561-967-5033 Fax: 561-967-8974 | |
Denzil S Seedial, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, Ste 204, Atlantis, FL 33462 Phone: 561-967-4118 Fax: 561-967-3463 | |
Dr. Daphnee Marie Hutchinson, D.O. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-1750 | |
Dr. Farahnaz Angella, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 180 Jfk Dr, Suite 311, Atlantis, FL 33462 Phone: 561-434-0353 Fax: 561-357-0869 |